Clinical Trial

Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)

Name: Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) — clinical trial record (NCT07548450)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MPOWER

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this clinical trial it to test the safety and tolerability of the study drugs mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.

Trial Details

NCT Number	NCT07548450
Lead Sponsor	University of Utah Collaborators: Genentech, Inc., Eli Lilly and Company
Conditions	Waldenstrom Macroglobulinemia
Enrollment	25 participants
Start Date	2026-06
Primary Completion	2034-06 (estimated)
Study Completion	2035-06 (estimated)
Updated on ClinicalTrials.gov	2026-04-23